Initial positive interim data revealed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma (PDAC) after experimental treatment with CAN-2409 Estimated overall survival rate was 71.4% at 36 months in CAN-2409 treated patients versus 16.7% in the control arm after chemoradiation In patients with progressive disease, there was both a CA19-9 and a survival response to salvage chemotherapy in the CAN-2409 arm, but not in the control arm.Dense aggregates of immune cells, including CD8 positive granzyme B positive cytotoxic T cells, dendritic cells, and B cells, were observed in PDAC tissue after CAN-2409 treatment, confirming activation of a robust antitumoral immune responseSafety analysis demonstrated that multiple injections of CAN-2409 were generally well tolerated, with no reported dose-limiting toxicities and no cases of pancreatitis NEEDHAM, Mass., Nov.

初步阳性中期数据显示，使用CAN-2409进行实验性治疗后，临界可切除胰腺导管腺癌（PDAC）患者的显着改善CAN-2409治疗患者36个月时的总生存率估计为71.4%，而对照组为16.7%放化疗后进展性疾病患者，CAN-2409组有CA19-9和挽救性化疗的生存反应，但对照组没有。在CAN-2409处理后，在PDAC组织中观察到密集的免疫细胞聚集体，包括CD8阳性颗粒酶B阳性细胞毒性T细胞，树突细胞和B细胞，证实了强烈的抗肿瘤免疫应答的激活。安全性分析表明多次注射CAN-2409通常耐受性良好，没有报道剂量限制性毒性，也没有胰腺炎病例NEEDHAM，Mass。，Nov。

03, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced initial positive interim survival and immunological biomarker data from the ongoing randomized phase 2 clinical trial of CAN-2409 plus valacyclovir (prodrug) together with standard of care (SoC) chemoradiation followed by resection for borderline resectable pancreatic ductal adenocarcinoma (PDAC).

032023（GLOBE NEWSWIRE）-Candel Therapeutics，Inc。（Candel或the Company）（纳斯达克：CADL），一家临床阶段生物制药公司，专注于开发病毒免疫疗法，帮助患者对抗癌症，今天宣布了正在进行的CAN-2409加伐昔洛韦（前药）与标准治疗（SoC）放化疗随后切除临界可切除胰腺导管腺癌（PDAC）的正在进行的随机2期临床试验的初始阳性中期存活和免疫生物标志物数据。

Data were presented today in a poster session titled ‘Neoadjuvant CAN-2409+Prodrug Plus Chemoradiation for Borderline Resectable or Locally Advanced Non-Metastatic Pancreatic Adenocarcinoma (PDAC) at the 2023 Society for Immunotherapy (SITC) Annual Meeting. “Given frequent recurrence and short survival with SoC chemotherapy for non-metastatic PDAC, effective .

数据今天在2023年免疫治疗学会（SITC）年会上的名为“新辅助CAN-2409+前药加放化疗治疗交界性可切除或局部晚期非转移性胰腺癌（PDAC）”的海报会议上发表。“对于非转移性PDAC，SoC化疗频繁复发且生存期短，有效。